What is lithium and its role as a mood‑stabilizing medication for bipolar disorder?

What is Lithium?

Lithium is a mood-stabilizing medication that serves as the gold standard first-line treatment for bipolar disorder, FDA-approved for treating acute mania and preventing mood episode recurrence in patients age 12 and older. 1

Mechanism of Action

Lithium alters sodium transport in nerve and muscle cells and shifts intraneuronal catecholamine metabolism, though its precise biochemical mechanism in treating mania remains incompletely understood 1. At the cellular level, lithium directly reduces elevated intracellular sodium concentrations—the most consistently reproduced biological abnormality during acute bipolar episodes—which may directly normalize the pathophysiology driving manic and depressive symptoms 2.

The drug modulates multiple neurotransmitter systems by:

• Reducing excitatory neurotransmission (dopamine and glutamate)
• Increasing inhibitory neurotransmission (GABA)
• Targeting second-messenger systems including adenyl cyclase and phospho-inositide pathways
• Inhibiting protein kinase C to dampen excessive neuronal excitation 3

Clinical Indications & Efficacy

FDA-Approved Uses

Lithium is indicated for 1:

• Acute manic episodes of Bipolar Disorder (symptom normalization typically within 1-3 weeks)
• Maintenance treatment to reduce frequency and intensity of mood episodes

Evidence-Based Effectiveness

Lithium demonstrates superior efficacy compared to other mood stabilizers in multiple domains 4:

• More effective than aripiprazole, valproic acid, and quetiapine for improving manic symptoms 5
• Lower relapse rates compared to valproic acid 5
• Unique anti-suicidal properties that distinguish it from all other psychiatric medications 6, 7
• Effective for preventing both manic AND depressive episodes (unlike many alternatives that primarily prevent mania) 7

The evidence shows lithium is effective in reducing suicide risk independent of its mood-stabilizing effects 6. This mortality benefit represents a critical quality-of-life consideration that should heavily influence prescribing decisions.

Prescribing Considerations

Patient Selection

Lithium should be initiated early in the disease course, as it functions as a disease-modifying agent that may alter illness trajectory and prevent progression 8. The drug preserves or increases volume in brain structures involved in emotional regulation (prefrontal cortex, hippocampus, amygdala), reflecting neuroprotective effects 3.

Dosing Strategy

• Initiate within 48 hours of admission for acute episodes—this significantly reduces hospital length of stay (7.2 vs 13.4 days) 9
• Optimize to therapeutic level-producing dose within 48 hours—further reduces length of stay (6.2 vs 9.1 days) 9
• Allow 6-8 week trial at adequate doses before adding or substituting other mood stabilizers 4

Therapeutic Ranges (Age-Specific)

• Ages 12-59: Standard therapeutic range
• Ages 60-79: 0.4-0.8 mmol/L 10
• Age 80+: 0.4-0.7 mmol/L 10

These lower ranges for older adults reduce toxicity risk while maintaining efficacy.

Monitoring Requirements

Baseline Assessment

Before initiating lithium 4:

• Complete blood count
• Thyroid function tests (TSH, T4)
• Urinalysis
• Blood urea nitrogen (BUN)
• Serum creatinine
• Serum calcium
• Pregnancy test (females of childbearing age)

Ongoing Monitoring

Once stable dose achieved 4:

• Lithium levels every 3-6 months
• Renal function (BUN, creatinine) every 3-6 months
• Thyroid function every 3-6 months
• Urinalysis every 3-6 months

Critical caveat: Periodic monitoring does not guarantee early detection of adverse effects. Educate patients and families about presenting symptoms of toxicity (diarrhea, vomiting, tremor, mild ataxia, drowsiness, muscular weakness) and instruct them to discontinue lithium and contact physician immediately if these occur 1.

Renal Considerations

Lithium enters collecting duct cells via epithelial sodium channels, disrupting vasopressin-regulated water handling and potentially causing 11:

• Nephrogenic diabetes insipidus (NDI)
• Polyuria
• Chronic tubulointerstitial nephropathy (minority of long-term users)

Risk amplifiers: Episodes of lithium intoxication, dehydration, medications reducing renal lithium clearance (NSAIDs, ACE inhibitors, diuretics), longer treatment duration 1, 11.

Maintenance Therapy Duration

Most youths with Bipolar I Disorder require ongoing medication therapy; some need lifelong treatment 4. Evidence shows:

• 90% of adolescents noncompliant with lithium relapsed vs. 37.5% who remained compliant 4

• Maintain acute stabilization regimen for 12-24 months minimum 4
• Withdrawal of lithium increases relapse risk, especially within 6 months of discontinuation 4

Any discontinuation attempt must be gradual with close monitoring for relapse. Educate patients/families on early warning signs of mood episodes 4.

Drug Interactions

High-risk combinations requiring dose adjustment or avoidance 1:

• Diuretics and ACE inhibitors: Reduce renal lithium clearance, increasing toxicity risk—decrease lithium dose and monitor levels more frequently
• NSAIDs (including COX-2 inhibitors): Increase lithium levels by ~17%; indomethacin and piroxicam have strongest effect—monitor levels closely when starting/stopping
• Haloperidol: Rare reports of encephalopathic syndrome—monitor closely for neurological toxicity
• Neuromuscular blocking agents: Lithium prolongs effects—use with caution

Special Populations

Pregnancy

Category D: Lithium crosses the placenta. Nursing should not be undertaken during lithium therapy as it is excreted in breast milk 1.

Children

Lithium is FDA-approved down to age 12 for acute mania and maintenance 4. Evidence in children is limited but generally positive, though risperidone and quetiapine showed superiority in some aspects for pediatric populations 5.

Older Adults

Use lower therapeutic ranges (see above) and monitor more frequently for renal dysfunction, as tolerance decreases with age 10.

Clinical Pitfalls to Avoid

1. Delaying initiation: Start lithium within 48 hours of admission for acute episodes to reduce morbidity and hospital stay 9

2. Inadequate patient education: Patients must understand to maintain normal salt intake and fluid intake (2500-3000 mL daily) during stabilization, and to supplement fluids/salt during sweating, diarrhea, or fever 1

3. Ignoring thyroid dysfunction: Pre-existing thyroid disorders don't contraindicate lithium, but require monitoring and potential supplemental thyroid treatment 1

4. Premature discontinuation: High relapse rates occur when lithium is stopped too early; maintain for minimum 12-24 months after stabilization 4

5. Overlooking suicide prevention benefit: Lithium's unique anti-suicidal properties represent a mortality benefit that should prioritize its use over alternatives lacking this effect 6, 7